JP2023543299A5 - - Google Patents
Info
- Publication number
- JP2023543299A5 JP2023543299A5 JP2023519522A JP2023519522A JP2023543299A5 JP 2023543299 A5 JP2023543299 A5 JP 2023543299A5 JP 2023519522 A JP2023519522 A JP 2023519522A JP 2023519522 A JP2023519522 A JP 2023519522A JP 2023543299 A5 JP2023543299 A5 JP 2023543299A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- compound
- acceptable salt
- available
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085384P | 2020-09-30 | 2020-09-30 | |
| US63/085,384 | 2020-09-30 | ||
| PCT/EP2021/076752 WO2022069520A1 (en) | 2020-09-30 | 2021-09-29 | Compounds and their use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543299A JP2023543299A (ja) | 2023-10-13 |
| JP2023543299A5 true JP2023543299A5 (enExample) | 2024-10-07 |
Family
ID=78085628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519522A Pending JP2023543299A (ja) | 2020-09-30 | 2021-09-29 | 化合物及び癌の治療におけるそれらの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230374007A1 (enExample) |
| EP (1) | EP4221756A1 (enExample) |
| JP (1) | JP2023543299A (enExample) |
| KR (1) | KR20230079408A (enExample) |
| CN (1) | CN116249554A (enExample) |
| AU (2) | AU2021353968B2 (enExample) |
| BR (1) | BR112023005708A2 (enExample) |
| CA (1) | CA3195695A1 (enExample) |
| CL (1) | CL2023000881A1 (enExample) |
| CO (1) | CO2023005188A2 (enExample) |
| CR (1) | CR20230185A (enExample) |
| DO (1) | DOP2023000062A (enExample) |
| EC (1) | ECSP23030959A (enExample) |
| IL (1) | IL301626A (enExample) |
| MX (1) | MX2023003564A (enExample) |
| PE (1) | PE20230782A1 (enExample) |
| WO (1) | WO2022069520A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115141179B (zh) * | 2021-03-31 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用 |
| US20250205344A1 (en) | 2022-03-24 | 2025-06-26 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl deratives as degrons in protacs |
| USD1018747S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1020957S1 (en) * | 2022-04-15 | 2024-04-02 | Puttshack LTD | Miniature golf hole |
| USD1018746S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1018676S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| US20260098043A1 (en) * | 2022-09-14 | 2026-04-09 | Hainan Simcere Zaiming Pharmeceutical Co., Ltd. | Polycyclic compound and use thereof |
| TW202508568A (zh) | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Ｉｒａｋ４蛋白水解靶向嵌合體 |
| PE20260301A1 (es) | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| PE20260307A1 (es) * | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| CN121773112A (zh) * | 2023-08-17 | 2026-03-31 | 海思科医药集团股份有限公司 | 一种氰基芳香环衍生物及其在医药上的应用 |
| TW202530192A (zh) | 2023-09-22 | 2025-08-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 新穎化合物 |
| CN117430605A (zh) * | 2023-10-26 | 2024-01-23 | 广西天铭药业有限公司 | 一种kras g12c抑制剂amg-510中间体的合成方法 |
| WO2025114875A1 (en) * | 2023-12-01 | 2025-06-05 | Astrazeneca Ab | Er degraders and uses thereof |
| WO2025125575A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422263D0 (en) | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| WO2014210255A1 (en) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019057757A1 (en) * | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN120698983A (zh) * | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
-
2021
- 2021-09-29 CA CA3195695A patent/CA3195695A1/en active Pending
- 2021-09-29 CR CR20230185A patent/CR20230185A/es unknown
- 2021-09-29 PE PE2023001220A patent/PE20230782A1/es unknown
- 2021-09-29 EP EP21787317.3A patent/EP4221756A1/en active Pending
- 2021-09-29 AU AU2021353968A patent/AU2021353968B2/en active Active
- 2021-09-29 CN CN202180065971.2A patent/CN116249554A/zh active Pending
- 2021-09-29 MX MX2023003564A patent/MX2023003564A/es unknown
- 2021-09-29 WO PCT/EP2021/076752 patent/WO2022069520A1/en not_active Ceased
- 2021-09-29 IL IL301626A patent/IL301626A/en unknown
- 2021-09-29 BR BR112023005708A patent/BR112023005708A2/pt unknown
- 2021-09-29 US US18/247,014 patent/US20230374007A1/en active Pending
- 2021-09-29 JP JP2023519522A patent/JP2023543299A/ja active Pending
- 2021-09-29 KR KR1020237014514A patent/KR20230079408A/ko active Pending
-
2023
- 2023-03-24 DO DO2023000062A patent/DOP2023000062A/es unknown
- 2023-03-27 CL CL2023000881A patent/CL2023000881A1/es unknown
- 2023-04-24 CO CONC2023/0005188A patent/CO2023005188A2/es unknown
- 2023-04-27 EC ECSENADI202330959A patent/ECSP23030959A/es unknown
-
2025
- 2025-01-09 AU AU2025200137A patent/AU2025200137A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543299A5 (enExample) | ||
| CA2732797C (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
| ES2885003T3 (es) | Estimuladores de SGC fusionados bicíclicos | |
| US9199979B2 (en) | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| US20230339902A1 (en) | Tricyclic ligands for degradation of ikzf2 or ikzf4 | |
| JP2019529484A5 (enExample) | ||
| PH12014502369B1 (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| AR049427A1 (es) | Compuestos de tiourea sustituidos con azabenzofurano, inhibidores de replicacion viral | |
| JP2020505396A5 (enExample) | ||
| JP2022191259A (ja) | キナーゼネットワークの阻害剤およびその使用 | |
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| CA2493225A1 (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| JP2017518981A5 (enExample) | ||
| JP2007501825A (ja) | キナーゼ阻害剤として活性なピリジルピロール誘導体 | |
| JP2006524662A5 (enExample) | ||
| WO2019224773A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| CN111214468B (zh) | 新型药物组合物及其用途 | |
| JP2015535247A5 (enExample) | ||
| EP3212651A1 (en) | Administration of ubiquitin-activating enzyme inhibitor and radiation | |
| JP2011513475A5 (enExample) | ||
| TW201244714A (en) | PARP inhibitors for the treatment of CIPN | |
| WO2019224774A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| CA2951798C (en) | Febrifugine derivatives and their use as prolyl-trna synthetase (prs) inhibitors | |
| US20260055114A1 (en) | Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases |